学术探索
学术期刊
新闻热点
数据分析
智能评审

mCICR is required for As2O3-induced permeability transition pore opening and cytochrome c release from mitochondria

被引：5
作者：
Xuemei Tian
Xiaodong Ma
Dongfang Qiao
Ande Ma
Fang Yan
Xingxu Huang
机构：
[1] Southern Medical University,Deparment of Histology and Embryology
[2] Southern Medical University,Central Laboratory
[3] Southern Medical University,Deparment of Histology and Embryology, Central Laboratory
来源：
Molecular and Cellular Biochemistry | 2005年 / 277卷
关键词：
As; O; calcium transport; cytochrome c; apoptosis; permeability transition pore; mitochondria;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The permeability transition pore (PTP) is central for apoptosis by acting as a good candidate pathway for the release of Cyt. c and apoptosis induction factors (AIF). Arsenite induces apoptosis via a direct effect on PTP. To characterize the exact mechanism for arsenite induces PTP opening, the effect of Ca2+ on As2O3-induced PTP opening, the relationship between As2O3-induced PTP opening and Cyt. c release from mitochondria and calcium-induced calcium release from mitochondria (mCICR), and the effects of As2O3 on Ca2+-induced PTP opening were studied. The results showed As2O3 induces Cyt. c release by triggering PTP opening. Ca2+ is necessary for As2O3-induced PTP opening. As2O3-induced PTP opening and Cyt. c release depends on mCICR. As2O3 promotes PTP opening by lowering Ca2+-threshold. These results indicated As2O3 induce Cyt. c release from mitochondria by lowering Ca2+-threshold for PTP and triggering mCICR-dependent PTP opening. Suggesting that it is possible to control apoptosis by altering Ca2+ threshold and mCICR to modulate PTP opening and Cyt. c release.
引用
收藏
页码：33 / 42
页数：9
相关论文
共 281 条
[1]  
Aposhian HV(1997)Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity Annu Rev Pharmacol Toxicol 37 397-419
[2]  
Soignet SL(1998)Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide N Engl J Med 339 1341-1348
[3]  
Maslak P(2004)The potential of arsenic trioxide in the treatment of malignant disease: Past, present, and future Leuk Res 28 891-900
[4]  
Wang ZG(2005)Acute promyelocytic leukemia: Recent advances in therapy and molecular basis of response to arsenic therapies Curr Opin Hematol 12 1-6
[5]  
Jhanwar S(1996)In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As Blood 88 1052-1061
[6]  
Calleja E(1999)O Mol Cell Biol 7 5170-5178
[7]  
Dardashti LJ(1997)) induces NB4 cell apoptosis with down-regulation of bcl-2 expression and modulation of PML-RAR alpha/PML proteins Blood 90 562-570
[8]  
Corso D(1998)PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia Br J Haematol 102 1055-1060
[9]  
De Blasio A(1999)Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines FEBS Lett 455 59-62
[10]  
Gabrilove J(2002)Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein Int J Oncol 21 57-63
12345678910